





In re Application of:

Judi BRYANT et al.

Serial No.: 10/722,591

Group Art Unit: 1615

Filed: November 28, 2002

Examiner:BALASUBRAMANIAN,

Venkataraman

For: CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND

USE AS PHARMACEUTICAL AGENTS

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

冈

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

## Timing and Fees

Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:						
	within three months of the filing date of a national application other than a CPA under § 1.53(d);					
	within three months of the actual filing date of the national phase of a PCT application; OR					
	before the mailing of a first substantive office action (including after filing of an RCE).					

Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:

a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and

08/15/2007 MAHHED1 00000124 10722591

01 FC:1806

180.00 OP

		is acco	mpanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
		$\boxtimes$	a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a r	notice of allowance under 37 C.F.R. § 1.311;
	AND i	is filed o	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).
Staten	nents U	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited	Materia	<u>ls</u>	
		ancest	of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
		-	s of materials listed but not attached were cited in an international search dated
		Not re	quired by 37 CFR § 1.98.
	$\boxtimes$	Copies	s of the materials listed are attached (except for the foregoing).

Non-E	nglish I	Language References					
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).					
		A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:					
		<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another such document</li> <li>A = document defining the general state of the art</li> <li>O = non-written disclosure</li> <li>P = intercalated document</li> <li>T = document cited to understand the theory or principle underlying the invention</li> <li>E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date</li> <li>D = cited in the application</li> <li>L = cited for another reason</li> <li>&amp; = publication of member of same patent family</li> </ul>					
		Translation of other relevant information on foreign search report					
		[insert necessary translation here]					
Other	Informa	<u>ation</u>					
Payme	ent of Fe	ees Due (If Any):					
	A chec	ck for \$180.00 covering the fee identified above is attached.					
	Please	charge to Deposit Account No. 13-3402 \$ for the fee identified above.					

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

/Csaba Henter/

Csaba Henter, Reg. No. 50,908 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza l
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1995

Date: August 14, 2007

CH:pdr

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are

Substitute	for form 1449A/PTC	)		Complete if Known		
				Application Number	10/722,591	
INFO	RMATION	DIS	CLOSURE	Filing Date	November 28, 2002	
STAT	EMENT B	Y AF	PPLICANT	First Named Inventor	Judi BRYANT et al.	
			•	Group Art Unit	1615	
	(use as many she	ets as	necessary)	Examiner Name	BALASUBRAMANIAN, Venkataraman	
Sheet	1	of	1	Attorney Docket Number SCH-1995		

U.S. PATENT DOCUMENTS							
Examiner Initials *	Cite No.1	U.S. Patent Docu	ment Kind Code <sup>2</sup> ( <i>if known</i> )	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document  MM-DD-YYYY		
	1	6,908,920		Thomas et al.	06-21-2005		
	2	6,906,065		Andrew Peter Thomas	06-14-2005		
		•					
		•					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.¹	Office <sup>3</sup>	oreign Patent Docum	Kind	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	3	WO	02/04429		Astrazeneca UK Limited	01-17-2002		Equiv to Cite 1
	4	wo	01/72717		Astrazeneca UK Limited	10-04-2001		Equiv to Cite 2

Examiner	Date
Signature	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.